Behavioral and Psychiatric Symptoms of Dementia and Rate of Decline in Alzheimer’s Disease

Alzheimer's disease causes both cognitive and non-cognitive symptoms. There is increasing evidence that the presentation and course of Alzheimer's disease is highly heterogenous. This heterogeneity presents challenges to patients, their families, and clinicians due to the difficulty in pro...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 10; p. 1062
Main Authors Gottesman, Reena T., Stern, Yaakov
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 24.09.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Alzheimer's disease causes both cognitive and non-cognitive symptoms. There is increasing evidence that the presentation and course of Alzheimer's disease is highly heterogenous. This heterogeneity presents challenges to patients, their families, and clinicians due to the difficulty in prognosticating future symptoms and functional impairment. Behavioral and psychiatric symptoms are emerging as a significant contributor to this clinical heterogeneity. These symptoms have been linked to multiple areas of neurodegeneration, which may suggest that they are representative of network-wide dysfunction in the brain. However, current diagnostic criteria for Alzheimer's disease focus exclusively on the cognitive aspects of disease. Behavioral and psychiatric symptoms have been found in multiple studies to be related to disease severity and to contribute to disease progression over time. A better understanding of how behavioral and psychiatric symptoms relate to cognitive aspects of Alzheimer's disease would help to refine the models of disease and hopefully lead to improved ability to develop therapeutic options for this devastating disease.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Reviewed by: Kurt A. Jellinger, University of Vienna, Austria; Lucio Tremolizzo, University of Milano-Bicocca, Italy
This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology
Edited by: Lydia Gimenez-Llort, Autonomous University of Barcelona, Spain
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2019.01062